

6 Literaturverzeichnis

- [1] Aicher T: Experimentelle Untersuchungen zur Wachstumsbeeinflussung von Monolayerzellen der oxyphilen, papillären Schilddrüsenkarzinomzelllinie ONCO-DG-1 durch TSH, EGF und den Anti-EGF-Rezeptor-Antikörper MAK 425. Med. Dissertation, Fakultät für Medizin, TU München, 1998.
- [2] ASCO 2003: Cetuximab (C225, EGF-Antikörper) wirksam allein und in Kombination mit Irinotecan auch bei Irinotecan-resistentem, EGFR+ metastasierten colorektalen Karzinom. Chicago, Innere Klinik-Tumorforschung 2003;S. 1012.
- [3] Asokan R, Reddy GK, Dhar SC: Studies on the intracellular degradation of newly synthesized collagen in 3-methylcholanthrene induced fibrosarcoma cells. *Life Sci* 1992; 51(13):1065-1071.
- [4] Banati RB, Rothe G, Valet G et al.: Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. *Glia* 1993; 7(2):183-191.
- [5] Baricos WH, Cortez SL, Le QC et al.: Glomerular basement membrane degradation by endogenous cysteine proteinases in isolated rat glomeruli. *Kidney Int* 1990; 38(3):395-401.
- [6] Barrett AJ: Proteinases in mammalian cells and tissues. North-Holland, Biochemical Press 1977; 123(2):134-138.
- [7] Barrett AJ: Cathepsin D: the lysosomal aspartic proteinase. *Ciba Found Symp* 1979; 75: 37-50.
- [8] Bennett MJ, Chern L, Carpenter KH et al.: Abnormal lysosomal cathepsin activities in leukocytes and cultured skin fibroblasts in late infantile, but not in juvenile neuronal ceroid-lipofuscinosis (Batten disease). *Clin Chim Acta* 1992; 208(1-2):111-117.
- [9] Bernstein HG, Kirschke H, Wiederanders B et al.: Lysosomal proteinases as putative diagnostic tools in human neuropathology: Alzheimer disease (AD) and schizophrenia. *Acta Histochem (Suppl)* 1992; 42:19-24.
- [10] Bohley P, Seglen PO: Proteases and proteolysis in the lysosome. *Experientia* 1992; 48(2):151-157.
- [11] Boujrad N, Ogwuegbu SO, Garnier M et al.: Identification of a stimulator of steroid hormone synthesis isolated from testis. *Science* 1995; 268(5217):1609-1612.
- [12] Bourke JR, Murdoch S, Manley SW et al.: Epidermal growth factor (EGF) inhibits the secretomotor response of the thyroid: effects of EGF on radioiodine turnover and fluid transport in cultured porcine thyroid cells. *J Endocrinol* 1991; 128(2):213-218.
- [13] Brix K, Lemansky P, Herzog V: Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. *Endocrinology* 1996; 137(5):1963-1974.
- [14] Brix K, Lemansky P, Herzog V: Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. *Endocrinology* 1996; 137(5):1963-1974.
- [15] Brock TD, Freeze H: *Thermus aquaticus* gen. n. and sp. n., a nonsporulating extreme thermophile. *J Bacteriol* 1969; 98(1):289-297.
- [16] Brzezinski J, Lewinski A: Increased plasma concentration of epidermal growth factor in female patients with non-toxic nodular goitre. *Eur J Endocrinol* 1998; 138(4):388-393.
- [17] Butkiewicz NJ, Wendel M, Zhang R et al.: Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity. *Virology* 1996; 225(2):328-338.
- [18] Buttle DJ, Saklatvala J: Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation. *Biochem J* 1992; 287 (Pt 2):657-661.
- [19] Carmona C, Dowd AJ, Smith AM et al.: Cathepsin L proteinase secreted by *Fasciola hepatica* in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. *Mol Biochem Parasitol* 1993; 62(1):9-17.
- [20] Castiglioni T, Merino MJ, Elsner B et al.: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. *Hum Pathol* 1994; 25(9):857-862.

- [21] Chapman HA, Jr., Munger JS, Shi GP: The role of thiol proteases in tissue injury and remodeling. *Am J Respir Crit Care Med* 1994; 150(6 Pt 2):S155-S159.
- [22] Chauhan SS, Goldstein LJ, Gottesman MM: Expression of cathepsin L in human tumors. *Cancer Res* 1991; 51(5):1478-1481.
- [23] Clark OH, Gerend PL, Davis M et al.: Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue. *J Surg Res* 1985; 38(2):89-96.
- [24] Clark OH, Siperstein AE, Miller R et al.: Receptors and Receptor-Transducing Systems in Normal and Neoplastic Human Thyroid Tissue. 2005.
- [25] Conover CA, De Leon DD: Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. *J Biol Chem* 1994; 269(10):7076-7080.
- [26] Coulombe R, Grochulski P, Sivaraman J et al.: Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. *EMBO J* 1996; 15(20):5492-5503.
- [27] Coulonval K, Vandeput F, Stein RC et al.: Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. *Biochem J* 2000; 348 (Pt 2):351-358.
- [28] Coulonval K, Vandeput F, Stein RC et al.: Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. *Biochem J* 2000; 348 (Pt 2):351-358.
- [29] Cox SW, Eley BM: Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid. A comparison of levels before and after basic periodontal treatment of chronic periodontitis patients. *J Clin Periodontol* 1992; 19(5):333-339.
- [30] Dalton JP, Clough KA, Jones MK et al.: Characterization of the cathepsin-like cysteine proteinases of *Schistosoma mansoni*. *Infect Immun* 1996; 64(4):1328-1334.
- [31] Dalton JP, McGonigle S, Rolph TP et al.: Induction of protective immunity in cattle against infection with *Fasciola hepatica* by vaccination with cathepsin L proteinases and with hemoglobin. *Infect Immun* 1996; 64(12):5066-5074.
- [32] Dano K, Andreasen PA, Grondahl-Hansen J et al.: Plasminogen activators, tissue degradation, and cancer. *Adv Cancer Res* 1985; 44:139-266.
- [33] Danser AH, Saris JJ, Schuijt MP et al.: Is there a local renin-angiotensin system in the heart? *Cardiovasc Res* 1999; 44(2):252-265.
- [34] Daughaday WH: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. *Endocrinology* 1990; 127(1):1-4.
- [35] Day SR, Dalton JP, Clough KA et al.: Characterization and cloning of the cathepsin L proteinases of *Schistosoma japonicum*. *Biochem Biophys Res Commun* 1995; 217(1):1-9.
- [36] Dehrmann FM, Coetzer TH, Pike RN et al.: Mature cathepsin L is substantially active in the ionic milieu of the extracellular medium. *Arch Biochem Biophys* 1995; 324(1):93-98.
- [37] Deiss LP, Galinka H, Berissi H et al.: Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. *EMBO J* 1996; 15(15):3861-3870.
- [38] Deleu S, Pirson I, Clermont F et al.: Immediate early gene expression in dog thyrocytes in response to growth, proliferation, and differentiation stimuli. *J Cell Physiol* 1999; 181(2):342-354.
- [39] Deleu S, Pirson I, Coulonval K et al.: IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. *Mol Cell Endocrinol* 1999; 149(1-2):41-51.
- [40] Dennison C, Pike R, Coetzer T et al.: Characterisation of the activity and stability of single-chain cathepsin L and of proteolytically active cathepsin L/cystatin complexes. *Biol Chem Hoppe Seyler* 1992; 373(7):419-425.
- [41] Dieling-Mavridis B: Insulin-like Growth Factor I (IGF-1) als Serummarker bei Malignomen. *Med. Dissertation, Fakultät für Medizin, TU München, 1998.*
- [42] Diment S, Eidelman M, Rodriguez GM et al.: Lysosomal hydrolases are present in melanosomes and are elevated in melanizing cells. *J Biol Chem* 1995; 270(9):4213-4215.

- [43] Donatien PD, Diment SL, Boissy RE et al.: Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-rasHa oncogene. *Int J Cancer* 1996; 66(4):557-563.
- [44] Drake FH, Dodds RA, James IE et al.: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. *J Biol Chem* 1996; 271(21):12511-12516.
- [45] Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. *Clin Exp Metastasis* 1992; 10(3):145-155.
- [46] Dumont JE, Lefort A, Libert F et al.: Transducing systems in the control of human thyroid cell function, proliferation and differentiation. *Adv Exp Med Biol* 1989; 261:357-372.
- [47] Dunn AD, Crutchfield HE, Dunn JT: Proteolytic processing of thyroglobulin by extracts of thyroid lysosomes. *Endocrinology* 1991; 128(6):3073-3080.
- [48] Dunn AD, Crutchfield HE, Dunn JT: Thyroglobulin processing by thyroidal proteases. Major sites of cleavage by cathepsins B, D, and L. *J Biol Chem* 1991; 266(30):20198-20204.
- [49] Dunn AD, Dunn JT: Cysteine proteinases from human thyroids and their actions on thyroglobulin. *Endocrinology* 1988; 123(2):1089-1097.
- [50] Dunn AD, Myers HE, Dunn JT: The combined action of two thyroidal proteases releases T4 from the dominant hormone-forming site of thyroglobulin. *Endocrinology* 1996; 137(8):3279-3285.
- [51] Ebisui C, Tsujinaka T, Morimoto T et al.: Changes of proteasomes and cathepsins activities and their expression during differentiation of C2C12 myoblasts. *J Biochem (Tokyo)* 1995; 117(5):1088-1094.
- [52] Eccles SAMH, Court Wea: Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor. In: Lichtner RB, (Ed.): *EGF Receptor in Tumor Growth and Progression*. Springer, Berlin - Heidelberg - New York - Barcelona - Budapest - Hong Kong - London - Milan - Paris - Santa Clara - Singapore - Tokyo, 1997, pp. 185-251.
- [53] Eley BM, Cox SW: Correlation of gingival crevicular fluid proteases with clinical and radiological measurements of periodontal attachment loss. *J Dent* 1992; 20(2):90-99.
- [54] Felbor U, Kessler B, Mothes W et al.: Neuronal loss and brain atrophy in mice lacking cathepsins B and L. *Proc Natl Acad Sci U S A* 2002; 99(12):7883-7888.
- [55] Fineschi B, Sakaguchi K, Appella E et al.: The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain. *J Immunol* 1996; 157(8):3211-3215.
- [56] Foghsgaard L, Wissing D, Mauch D et al.: Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. *J Cell Biol* 2001; 153(5):999-1010.
- [57] Frade R, Rodrigues-Lima F, Huang S et al.: Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. *Cancer Res* 1998; 58(13):2733-2736.
- [58] Führer DPR: Mutationen im TSH-Rezeptorgen: Pathogenetische Bedeutung und klinische Relevanz. *Deutsche Medizinische Wschr* 1999; 124(21):662-669.
- [59] Fujita J, Tsujinaka T, Yano M et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. *Int J Cancer* 1996; 68(5):637-643.
- [60] Gabrijelcic D, Svetic B, Spaic D et al.: Cathepsins B, H and L in human breast carcinoma. *Eur J Clin Chem Clin Biochem* 1992; 30(2):69-74.
- [61] Gabrijelcic D, Svetic B, Spaic D et al.: Cathepsins B, H and L in human breast carcinoma. *Eur J Clin Chem Clin Biochem* 1992; 30(2):69-74.
- [62] Gerstner AOH: Untersuchungen zum Einfluß von Insulin, IGF-1 und IGF-2 auf Proliferation und Differenzierung von Zelllinien kleinzelliger Bronchialkarzinome. *Med. Dissertation, Fachbereich Humanmedizin, Philipps-Universität Marburg*, 1996.
- [63] Goretzki L, Schmitt M, Mann K et al.: Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. *FEBS Lett* 1992; 297(1-2):112-118.

- [64] Goretzki PE, Frilling A, Simon D et al.: Growth Regulation of Human Thyrocytes by Thyrotropin, Cyclic Adenosine Monophosphate, Epidermal Growth Factor and Insulin-Like Growth Factor. In: Goretzki PE, Röher HD (Eds): *Frontiers of Hormone Research: Growth Regulation of Thyroid Gland and Thyroid Tumors*. Karger, Basel 1989, pp. 56-80.
- [65] Goto T, Kiyoshima T, Moroi R et al.: Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy. *Histochemistry* 1994; 101(1):33-40.
- [66] Graeff H, Janicke F, Schmitt M: Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology. *Geburtshilfe Frauenheilkd* 1991; 51(2):90-99.
- [67] Graf N: Alveoläre Permeabilitätsstörung nach Granulozytenstimulation durch Phorbol-Myristat-Azetat (PMA) im Kaninchen. Med. Dissertation, Fachbereich Humanmedizin, Georg-August-Universität zu Göttingen, 1991.
- [68] Guinec N, Dalet-Fumeron V, Pagano M: "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. *Biol Chem Hoppe Seyler* 1993; 374(12):1135-1146.
- [69] Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. *Br Med Bull* 1991; 47(1):87-98.
- [70] Gustavsson B, Hermansson A, Andersson AC et al.: Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. *Mol Cell Endocrinol* 1996; 121(2):143-151.
- [71] Haas A: Quantitative Untersuchungen tumorassoziierter Proteolysefaktoren (Kathepsin B und D, uPA, uPA-Rezeptor, PAI-1) mittels Durchflußzytofluorometrie (FACScan). Med. Dissertation, Fakultät für Medizin, TU München, 1997.
- [72] Halangk W: Cathepsin B-induced versus trypsin-induced protease activation in the exocrine pancreas. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;21.
- [73] Hale AJ, Smith CA, Sutherland LC et al.: Apoptosis: molecular regulation of cell death. *Eur J Biochem* 1996; 236(1):1-26.
- [74] Harris AL: EGF Receptors as a Target for Therapy and Interactions with Angiogenesis. In: Lichtner RB, (Ed): *EGF Receptor in Tumor Growth and Progression*. Springer, Berlin - Heidelberg - New York - Barcelona - Budapest - Hong Kong - London - Milan - Paris - Santa Clara - Singapore - Tokyo, 1997, pp. 89-103.
- [75] Harth G, Andrews N, Mills AA et al.: Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of *Trypanosoma cruzi*. *Mol Biochem Parasitol* 1993; 58(1):17-24.
- [76] Haugen DR, Akslen LA, Varhaug JE et al.: Demonstration of a TGF- α -EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. *Int J Cancer* 1993; 55(1):37-43.
- [77] Hayes DJ, Stubberfield CR, McBride JD et al.: Alterations in cysteine proteinase content of rat lung associated with development of *Pneumocystis carinii* infection. *Infect Immun* 1991; 59(10):3581-3588.
- [78] Heidtmann HH, Salge U, Havemann K et al.: Secretion of a latent, acid activatable cathepsin L precursor by human non-small cell lung cancer cell lines. *Oncol Res* 1993; 5(10-11):441-451.
- [79] Heldin NE, Cvejic D, Smeds S et al.: Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. *Endocrinology* 1991; 129(4):2187-2193.
- [80] Heldin NE, Gustavsson B, Claesson-Welsh L et al.: Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. *Proc Natl Acad Sci U S A* 1988; 85(23):9302-9306.
- [81] Hoang-Vu C, Bull K, Schwarz I et al.: Regulation of CD97 protein in thyroid carcinoma. *J Clin Endocrinol Metab* 1999; 84(3):1104-1109.

- [82] Hofmann A, Laue S, Rost AK et al.: mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. *Thyroid* 1998; 8(3):203-214.
- [83] Homma K, Kurata S, Natori S: Purification, characterization, and cDNA cloning of procathepsin L from the culture medium of NIH-Sape-4, an embryonic cell line of *Sarcophaga peregrina* (flesh fly), and its involvement in the differentiation of imaginal discs. *J Biol Chem* 1994; 269(21):15258-15264.
- [84] Howie AF, Arthur JR, Nicol F et al.: Identification of a 57-kilodalton selenoprotein in human thyrocytes as thioredoxin reductase and evidence that its expression is regulated through the calcium-phosphoinositol signaling pathway. *J Clin Endocrinol Metab* 1998; 83(6):2052-2058.
- [85] Ishidoh K, Kominami E: Multi-step processing of procathepsin L in vitro. *FEBS Lett* 1994; 352(3):281-284.
- [86] Ito T, Seyama T, Hayashi Y et al.: Unique association of p53 mutations with undifferentiated carcinoma of the thyroid. *Nippon Rinsho* 1994; 52(4):1069-1074.
- [87] Jane DT, Dufresne MJ: Expression and regulation of three lysosomal cysteine protease activities during growth of a differentiating L6 rat myoblast cell line and its nonfusing variant. *Biochem Cell Biol* 1994; 72(7-8):267-274.
- [88] Jhiang SM: The RET proto-oncogene in human cancers. *Oncogene* 2000; 19(49):5590-5597.
- [89] Jimi T, Satoh Y, Takeda A et al.: Strong immunoreactivity of cathepsin L at the site of rimmed vacuoles in diseased muscles. *Brain* 1992; 115 (Pt 1):249-260.
- [90] Jochum M, Gippner-Steppert C, Machleidt W et al.: The role of phagocyte proteinases and proteinase inhibitors in multiple organ failure. *Am J Respir Crit Care Med* 1994; 150 (Pt 2):123-S130.
- [91] Joseph LJ, Chang LC, Stamenkovich D et al.: Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts. *J Clin Invest* 1988; 81(5):1621-1629.
- [92] Jungheim C: Effekte von TSH, TSH-Rezeptor-Antikörpern und Interferon-alpha-2b auf die Proliferation von differenzierten Schilddrüsenkarzinomen im Nacktmausversuch. Med. Dissertation, Fachbereich Humanmedizin, J.-W.-Goethe-Universität, 1999.
- [93] Kageshita T, Yoshii A, Kimura T et al.: Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. *Arch Dermatol Res* 1995; 287(3-4):266-272.
- [94] Kakegawa H, Nikawa T, Tagami K et al.: Participation of cathepsin L on bone resorption. *FEBS Lett* 1993; 321(2-3):247-250.
- [95] Kantak M: Epidermaler Wachstumsfaktor (EGF) im Serum von Patienten mit benignen und malignen Erkrankungen. Med. Dissertation, Fachbereich Humanmedizin, Justus-Liebig-Universität Giessen, 1997.
- [96] Kasai M, Shirasawa T, Kitamura M et al.: Proenzyme form of cathepsin L produced by thymic epithelial cells promotes proliferation of immature thymocytes in the presence of IL-1, IL-7, and anti-CD3 antibody. *Cell Immunol* 1993; 150(1):124-136.
- [97] Kayser L, Perrild H, Thomsen J et al.: Microfluorometric kinetic analysis of cathepsin B activity in single human thyroid follicular epithelial cells using image analysis and continuous monitoring. *Histochem J* 1996; 28(4):257-263.
- [98] Keyszer GM, Heer AH, Kriegsmann J et al.: Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. *Arthritis Rheum* 1995; 38(7):976-984.
- [99] Khazaie K: The Role of Epidermal Growth Factor Receptor in the Initiation and Progression of Malignancy. In: Lichtner RB, (Ed) *GF Receptor in Tumor Growth and Progression*. Springer, Berlin -Heidelberg - New York - Barcelona - Budapest - Hong Kong - London - Milan - Paris - Santa Clara - Singapore - Tokyo, 1997, pp. 165-184.

- [100] Kirschke H, Langner J, Wiederanders B et al.: Intrazellulärer Proteinabbau. IV. Isolierung und Charakterisierung von Peptidasen aus Rattenleberlysosomen. *Acta Biol Med Germ* 1972; 28:305-322.
- [101] Kirschke H, Langner J, Wiederanders B et al. Cathepsin L and proteinases with cathepsin B1-like activity from rat liver lysosomes. *Intracellular Protein Catabolism* , 210-217. 1974. Leipzig, Barth, J.A.
- [102] Kiyoshima T, Kido MA, Nishimura Y et al.: Immunocytochemical localization of cathepsin L in the synovial lining cells of the rat temporomandibular joint. *Arch Oral Biol* 1994; 39(12):1049-1056.
- [103] Knoch H: Die Cysteinproteinase Cathepsin B und Cysteinproteinase-Inhibitoren in Tumor- und Lungengewebe von Patienten mit Bronchialkarzinom und ihre mögliche Rolle bei der Tumorerkrankung und der Tumormetastasierung. Med. Dissertation, Fakultät für Klinische Medizin I, Ruprecht-Karls-Universität Heidelberg, 1996.
- [104] Kobayashi H, Schmitt M, Goretzki L et al.: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro- uPA). *J Biol Chem* 1991; 266(8):5147-5152.
- [105] Kopitz J, Arnold A, Meissner T et al.: Protein catabolism in fibroblasts cultured from patients with mucopolysaccharidosis II and other lysosomal disorders. *Biochem J* 1993; 295 (Pt 2):577-580.
- [106] Korem S, Resnick MB, Kraiem Z: Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. *J Clin Endocrinol Metab* 1999; 84(9):3322-3327.
- [107] Korte S, Rauscher M: Wachstumshormone - STH/hGH/IGF-1/Insulin. 1 ed. ISP Verlag, Arnberg, 2000.
- [108] Kraimps JL, Metaye T, Millet C et al.: Cathepsin D in normal and neoplastic thyroid tissues. *Surgery* 1995; 118(6):1036-1040.
- [109] Kremer M, Judd J, Rifkin B et al.: Estrogen modulation of osteoclast lysosomal enzyme secretion. *J Cell Biochem* 1995; 57(2):271-279.
- [110] Kroemer G, Jaattela M: Lysosomes and autophagy in cell death control. *Nat Rev Cancer* 2005; 5(11):886-897.
- [111] Krueger S, Kalinski T, Wolf H et al.: Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture--regulation of cathepsin B expression and invasiveness. *Cancer Lett* 2005; 223(2):313-322.
- [112] Krüger S e a: Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: Studies of uptake, toxicity and effects on the invasive phenotype. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;31.
- [113] Krüger S e a: Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;32.
- [114] Lah TT, Calaf G, Kalman E et al.: Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). *Biol Chem Hoppe Seyler* 1995; 376(6):357-363.
- [115] Lah TT, Kokalj-Kunovar M, Drobnic-Kosorok M et al.: Cystatins and cathepsins in breast carcinoma. *Biol Chem Hoppe Seyler* 1992; 373(7):595-604.
- [116] Lah TT, Kokalj-Kunovar M, Strukelj B et al.: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. *Int J Cancer* 1992; 50(1):36-44.
- [117] Lemansky P, Brix K, Herzog V: Iodination of mature cathepsin D in thyrocytes as an indicator for its transport to the cell surface. *Eur J Cell Biol* 1998; 76(1):53-62.
- [118] Leto G, Tumminello FM, Pizzolanti G et al.: Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. *Oncology* 1997; 54(1):79-83.
- [119] Lichtner RB, Harkins RN: EGF Receptor in Tumor Growth and Progression. Springer, Berlin - Heidelberg - New York - Barcelona - Budapest - Hong Kong - London - Milan - Paris - Santa Clara - Singapore - Tokyo, 1997.

- [120] Lichtner RB, Harkins RN: Signal Transduction by EGF Receptor Tyrosine Kinase. In: Lichtner RB, (Ed): EGF Receptor in Tumor Growth and Progression. Springer, Berlin - Heidelberg - New York - Barcelona - Budapest - Hong Kong - London - Milan - Paris - Santa Clara - Singapore - Tokyo, 1997, pp. 1-17.
- [121] Liotta LA, Tryggvason K, Garbisa S et al.: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 1980; 284(5751):67-68.
- [122] Lui WO, Kytola S, Anfalk L et al.: Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma? *Cancer Genet Cytogenet* 2000; 119(2):109-112.
- [123] Macaulay VM: Insulin-like growth factors and cancer. *Br J Cancer* 1992; 65(3):311-320.
- [124] Macaulay VM, Teale JD, Everard MJ et al.: Serum insulin-like growth factor-I levels in patients with small cell lung cancer. *Eur J Cancer Clin Oncol* 1988; 24(7):1241-1242.
- [125] Mainferme F, Wattiaux R, von Figura K: Synthesis, transport and processing of cathepsin C in Morris hepatoma 7777 cells and rat hepatocytes. *Eur J Biochem* 1985; 153(1):211-216.
- [126] Mark J, Ekedahl C, Dahlenfors R et al.: Cytogenetical observations in five human anaplastic thyroid carcinomas. *Hereditas* 1987; 107(2):163-174.
- [127] Mason RW, Massey SD: Surface activation of pro-cathepsin L. *Biochem Biophys Res Commun* 1992; 189(3):1659-1666.
- [128] Mazzieri R, Masiero L, Zanetta L et al.: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. *EMBO J* 1997; 16(9):2319-2332.
- [129] McKerrow JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. *Int J Parasitol* 1999; 29(6):833-837.
- [130] Metaye T, Kraimps JL, Goujon JM et al.: Expression, localization, and thyrotropin regulation of cathepsin D in human thyroid tissues. *J Clin Endocrinol Metab* 1997; 82(10):3383-3388.
- [131] Metaye T, Millet C, Kraimps JL et al.: Estrogen receptors and cathepsin D in human thyroid tissue. *Cancer* 1993; 72(6):1991-1996.
- [132] Michel A, Ghoneim H, Resto M et al.: Sequence, characterization and localization of a cysteine proteinase cathepsin L in *Schistosoma mansoni*. *Mol Biochem Parasitol* 1995; 73(1-2):7-18.
- [133] Minuto F, Barreca A, Del Monte P et al.: Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. *J Clin Endocrinol Metab* 1989; 68(3):621-626.
- [134] Mohamed MM, Cavallo-Medved D, Sloane BF: Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer. *Biol Chem* 2008.
- [135] Mohamed MM, Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. *Nat Rev Cancer* 2006; 6(10):764-775.
- [136] Mort JS, Recklies AD: Interrelationship of active and latent secreted human cathepsin B precursors. *Biochem J* 1986; 233(1):57-63.
- [137] Müller-Gärtner HW, Baisch H, Garn M et al.: Individually Different Proliferation Responses of Differentiated Thyroid Carcinomas to Thyrotropin. In: Goretzki PE, Röher HD, (Eds): *Frontiers of Hormone Research: Growth Regulation of Thyroid Gland and Thyroid Tumors*. Karger, Basel, 1989, pp. 137-151.
- [138] Mullins DE, Rohrich ST: The role of proteinases in cellular invasiveness. *Biochim Biophys Acta* 1983; 695(3-4):177-214.
- [139] Nagy N, Camby I, Decaestecker C et al.: The influence of L-triiodothyronine, L-thyroxine, estradiol-17beta, the luteinizing-hormone-releasing hormone, the epidermal growth factor and gastrin on cell proliferation in organ cultures of 35 benign and 13 malignant human thyroid tumors. *J Cancer Res Clin Oncol* 1999; 125(6):361-368.
- [140] Neal DE, Sharples L, Smith K et al.: The epidermal growth factor receptor and the prognosis of bladder cancer. *Cancer* 1990; 65(7):1619-1625.

- [141] Nicholson RI, Gee JMW, et al: erbB Signaling and Endocrine Sensitivity of Human Breast Cancer. In: Lichtner RB, (Hrsg): EGF Receptor in Tumor Growth and Progression. Springer, Berlin ; Heidelberg ; New York ; Barcelona ; Budapest ; Hong Kong ; London ; Milan ; Paris ; Santa Clara ; Singapore ; Tokyo, 1997, S 105-128.
- [142] Nicholson S, Halcrow P, Sainsbury JR et al.: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. *Br J Cancer* 1988; 58(6):810-814.
- [143] Nicholson S, Sainsbury JR, Halcrow P et al.: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. *Lancet* 1989; 1(8631):182-185.
- [144] Nishida Y, Kohno K, Kawamata T et al.: Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. *Gynecol Oncol* 1995; 56(3):357-361.
- [145] Nishimura Y, Kawabata T, Furuno K et al.: Evidence that aspartic proteinase is involved in the proteolytic processing event of procathepsin L in lysosomes. *Arch Biochem Biophys* 1989; 271(2):400-406.
- [146] Nishimura Y, Kawabata T, Yano S et al.: Inhibition of intracellular sorting and processing of lysosomal cathepsins H and L at reduced temperature in primary cultures of rat hepatocytes. *Arch Biochem Biophys* 1990; 283(2):458-463.
- [147] Ohmura E, Okada M, Onoda N et al.: Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. *Cancer Res* 1990; 50(1):103-107.
- [148] Olbricht CJ: Distribution of cathepsins B and L in the kidney and their role in tubular protein absorption. *Eur J Clin Chem Clin Biochem* 1992; 30(10):675-681.
- [149] Paczek L, Bartłomiejczyk I, Gradowska L et al.: Intraglomerular protein accumulation in chronically rejected human kidney allografts. *Transplant Proc* 1996; 28(6):3449-3451.
- [150] Paczek L, Pazik J, Gradowska L et al.: Intraglomerular cathepsin B and L activity in chronic kidney allograft rejection. *Transplant Proc* 1995; 27(1):932-933.
- [151] Pagano M, Capony F, Rochefort H: [Pro-cathepsin D can activate in vitro pro-cathepsin B secreted by ovarian cancers]. *C R Acad Sci III* 1989; 309(1):7-12.
- [152] Page AE, Hayman AR, Andersson LM et al.: Degradation of bone matrix proteins by osteoclast cathepsins. *Int J Biochem* 1993; 25(4):545-550.
- [153] Penttila TL, Hakovirta H, Mali P et al.: Follicle-stimulating hormone regulates the expression of cyclic protein-2/cathepsin L messenger ribonucleic acid in rat Sertoli cells in a stage-specific manner. *Mol Cell Endocrinol* 1995; 113(2):175-181.
- [154] Peters C e a: In Vivo Functions of Lysosomal Cysteine Proteinases. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;53.
- [155] Peyrat JP, Bonnetterre J, Beuscart R et al.: Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. *Cancer Res* 1988; 48(22):6429-6433.
- [156] Pietrzkowski Z, Mulholland G, Gomella L et al.: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. *Cancer Res* 1993; 53(5):1102-1106.
- [157] Pike RN, Coetzer TH, Dennison C: Proteolytically active complexes of cathepsin L and a cysteine proteinase inhibitor; purification and demonstration of their formation in vitro. *Arch Biochem Biophys* 1992; 294(2):623-629.
- [158] Plebani M, Herszenyi L, Cardin R et al.: Cysteine and serine proteases in gastric cancer. *Cancer* 1995; 76(3):367-375.
- [159] Prence EM, Dong JM, Sahagian GG: Modulation of the transport of a lysosomal enzyme by PDGF. *J Cell Biol* 1990; 110(2):319-326.
- [160] Radinsky R, Risin S, Fan D et al.: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. *Clin Cancer Res* 1995; 1(1):19-31.

- [161] Rassner UA: Das maligne Melanom der Haut und der epidermale Wachstumsfaktor (EGF): Ultrastrukturelle Lokalisierung des EGF im Melanom und Literaturübersicht. Med. Dissertation, Medizinische Fakultät, Eberhard-Karls-Universität, Tübingen, 1999.
- [162] Rauschnabel U: RGD-spezifische Bindung von insulin-ähnlichen Wachstumsfaktor Bindungsprotein 2 (IGFBP-2) an $\alpha 5\beta 1$ -Integrinrezeptoren auf der Oberfläche von Ewingsarkom Zellen und IGF-unabhängige Effekte. Dissertation, Fakultät für Biologie, Eberhards-Karls-Universität Tübingen, 2000.
- [163] Reddy GK, Dhar SC: Purification and characterization of collagenolytic property of renal cathepsin L from arthritic rat. *Int J Biochem* 1992; 24(9):1465-1473.
- [164] Reddy VY, Zhang QY, Weiss SJ: Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. *Proc Natl Acad Sci U S A* 1995; 92(9):3849-3853.
- [165] Rhoads ML, Fetterer RH: Developmentally regulated secretion of cathepsin L-like cysteine proteases by *Haemonchus contortus*. *J Parasitol* 1995; 81(4):505-512.
- [166] Ritonja A, Popovic T, Kotnik M et al.: Amino acid sequences of the human kidney cathepsins H and L. *FEBS Lett* 1988; 228(2):341-345.
- [167] Ritonja A, Popovic T, Turk V et al.: Amino acid sequence of human liver cathepsin B. *FEBS Lett* 1985; 181(1):169-172.
- [168] Rocchi P, Ferreri AM, Simone G et al.: Inhibitors of protein kinases induce differentiation in human neuroblastoma cell lines. *Anticancer Res* 1995; 15(4):1381-1385.
- [169] Ruettinger A, Schueler S, Mollenhauer JA et al.: Cathepsins B, K, and L Are Regulated by a Defined Collagen Type II Peptide via Activation of Classical Protein Kinase C and p38 MAP Kinase in Articular Chondrocytes. *J Biol Chem* 2008; 283(2):1043-1051.
- [170] Russo A, Bazan V, Gebbia N et al.: Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance. *Cancer* 1995; 76(10):1757-1764.
- [171] Saftig P et al.: Studies on the in vivo functions of cathepsins using mouse knockout models. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;60.
- [172] Sainsbury JR, Farndon JR, Needham GK et al.: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. *Lancet* 1987; 1(8547):1398-1402.
- [173] Scheven BA, Hamilton NJ, Fakkeldij TM et al.: Effects of recombinant human insulin-like growth factor I and II (IGF-I/-II) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. *Growth Regul* 1991; 1(4):160-167.
- [174] Schmid U: Untersuchungen zur Rezeptorbindung und biologischen Wirkung von Insulin, Lispro-Insulin und Insulin-like Growth Factor-1 (IGF-1) an proximalen Nierentubuluszellen. Med. Dissertation, Medizinische Fakultät der Universität Ulm, 1999.
- [175] Schmitt M, Jänicke F, Graeff H: Tumor-associated proteases. *Fibrinolysis* 1992; Suppl.4(6):3-26.
- [176] Schmutzler C, Koehrle J: Innovative strategies for the treatment of thyroid cancer. *Eur J Endocrinol* 2000; 143(1):15-24.
- [177] Schneider DL: ATP-dependent acidification of intact and disrupted lysosomes. Evidence for an ATP-driven proton pump. *J Biol Chem* 1981; 256(8):3858-3864.
- [178] Schober R, Bilzer T, Waha A et al.: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. *Clin Neuropathol* 1995; 14(3):169-174.
- [179] Schott-Göttelmann D: Expression von EGF, EGF-R und c-erbB-2 im humanen Pankreaskarzinom - klinische Bedeutung. Med. Dissertation, Medizinische Fakultät, Universität Ulm, 1999.
- [180] Schultz H: Phosphorylierung des kleinen Säugerhitzeschockproteins - Erzeugung und Charakterisierung von Antikörpern gegen Hsp25 und Hsp25-Phosphopeptid und Untersuchungen zur funktionellen Bedeutung der Hsp27-Phosphorylierung bei der PMA-induzierten Differenzierung von HL60-Zellen. Dissertation, Mathematisch-Naturwissenschaftliche Fakultät I, Humbolt-Universität, 1999.

- [181] Sehgal I, Thompson TC: Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. *Mol Biol Cell* 1999; 10(2):407-416.
- [182] Sheflin LG, Fucile NW, Ozawa S et al.: Thyroxine increases the levels of epidermal growth factor messenger ribonucleic acid (EGF mRNA) in the thyroid in vivo, as revealed by quantitative reverse transcription polymerase chain reaction with an internal control EGF mRNA. *Endocrinology* 1993; 132(6):2319-2324.
- [183] Shin DM, Perez-Soler RHWNHWK: Epidermal Growth Factor Receptor Expression in Head and Neck Tumorigenesis and Saturation of EGFR with Monoclonal Antibody RG83852. In: Lichtner RB, (Ed): *EGF Receptor in Tumor Growth and Progression*. Springer, Berlin, 1997, pp. 65-87.
- [184] Shuja S, Murnane MJ: Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. *Int J Cancer* 1996; 66(4):420-426.
- [185] Shuja S, Sheahan K, Murnane MJ: Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. *Int J Cancer* 1991; 49(3):341-346.
- [186] Sivaparvathi M, Sawaya R, Wang SW et al.: Overexpression and localization of cathepsin B during the progression of human gliomas. *Clin Exp Metastasis* 1995; 13(1):49-56.
- [187] Slack JM, Kuzio J, Faulkner P: Characterization of v-cath, a cathepsin L-like proteinase expressed by the baculovirus *Autographa californica* multiple nuclear polyhedrosis virus. *J Gen Virol* 1995; 76 (Pt 5):1091-1098.
- [188] Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235(4785):177-182.
- [189] Sloane BF: Cathepsin B and cystatins: evidence for a role in cancer progression. *Semin Cancer Biol* 1990; 1(2):137-152.
- [190] Sloane BF, Rozhin J, Moin K et al.: Cysteine endopeptidases and their inhibitors in malignant progression of rat embryo fibroblasts. *Biol Chem Hoppe Seyler* 1992; 373(7):589-594.
- [191] Sloane BF, Yan S, Podgorski I et al.: Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. *Semin Cancer Biol* 2005; 15(2):149-157.
- [192] Sloane B F e a: Observing Proteases and proteolysis in living tumor cells. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;65.
- [193] Smith AM, Carmona C, Dowd AJ et al.: Neutralization of the activity of a *Fasciola hepatica* cathepsin L proteinase by anti-cathepsin L antibodies. *Parasite Immunol* 1994; 16(6):325-328.
- [194] Smith AM, Dowd AJ, Heffernan M et al.: *Fasciola hepatica*: a secreted cathepsin L-like proteinase cleaves host immunoglobulin. *Int J Parasitol* 1993; 23(8):977-983.
- [195] Takahashi H, Ishidoh K, Muno D et al.: Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. *Am Rev Respir Dis* 1993; 147(6 Pt 1):1562-1568.
- [196] Takashi Ito YHTHea: Establishment of two human thyroid carcinoma cell lines (8305C, 8505C) bearing p53 gene mutations. *International Journal of Oncology* 1994;(4):583-586.
- [197] Talavera F, Reynolds RK, Roberts JA et al.: Insulin-like growth factor I receptors in normal and neoplastic human endometrium. *Cancer Res* 1990; 50(10):3019-3024.
- [198] Tanabe H, Kumagai N, Tsukahara T et al.: Changes of lysosomal proteinase activities and their expression in rat cultured keratinocytes during differentiation. *Biochim Biophys Acta* 1991; 1094(3):281-287.
- [199] Tanaka K, Inoue H, Miki H et al.: Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization. *Clin Endocrinol (Oxf)* 1996; 44(3):259-267.
- [200] Tanaka K, Inoue H, Miki H et al.: Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. *Br J Cancer* 1997; 76(5):594-599.

- [201] Taniguchi K, Tomita M, Kominami E et al.: Cysteine proteinases in rat dorsal root ganglion and spinal cord, with special reference to the co-localization of these enzymes with calcitonin gene-related peptide in lysosomes. *Brain Res* 1993; 601(1-2):143-153.
- [202] Tao K, Stearns NA, Dong J et al.: The proregion of cathepsin L is required for proper folding, stability, and ER exit. *Arch Biochem Biophys* 1994; 311(1):19-27.
- [203] Tardy C, Codogno P, Autefage H et al.: Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). *Biochim Biophys Acta* 2006; 1765(2):101-125.
- [204] Tchoupe JR, Moreau T, Gauthier F et al.: Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. *Biochim Biophys Acta* 1991; 1076(1):149-151.
- [205] Tepel C, Bromme D, Herzog V et al.: Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. *J Cell Sci* 2000; 113 (Pt 24):4487-4498.
- [206] Tepel C et al.: Sequence, localization and function of Cathepsin K in thyroid epithelial cells. 2nd Symposium of Cellular peptidases in immune functions and diseases, Magdeburg 1999;71.
- [207] Thomssen C, Schmitt M, Goretzki L et al.: Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. *Clin Cancer Res* 1995; 1(7):741-746.
- [208] Thomsson C: Tumorassoziierte Proteolyse: Untersuchungen zur prognostischen Bedeutung der Zysteinprotease Kathepsin L bei Patientinnen mit Mammakarzinom. Med. Dissertation, Fakultät für Medizin, TU München, 1997.
- [209] Thorgeirsson UP, Turpeenniemi-Hujanen T, Neckers LM et al.: Protein synthesis but not DNA synthesis is required for tumor cell invasion in vitro. *Invasion Metastasis* 1984; 4(2):73-83.
- [210] Timmermann M: Die Bedeutung des EGF-Rezeptors für die Prognose des primär nodal negativen Mammakarzinoms hinsichtlich des Auftretens von Fernmetastasen und lokoregionären Rezidiven. Med. Dissertation, Fachbereich Medizin, Universität Hamburg, 1999.
- [211] Tomomasa H, Waguri S, Umeda T et al.: Lysosomal cysteine proteinases in rat epididymis. *J Histochem Cytochem* 1994; 42(3):417-425.
- [212] Torre G, Barreca A, Borgonovo G et al.: Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: possible role of insulin-like growth factors and insulin-like growth factor-binding proteins. *Surgery* 2000; 127(1):99-103.
- [213] Trabandt A, Muller-Ladner U, Kriegsmann J et al.: Expression of proteolytic cathepsins B, D, and L in periodontal gingival fibroblasts and tissues. *Lab Invest* 1995; 73(2):205-212.
- [214] Tsao MS, Zhu H, Viallet J: Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells. *Exp Cell Res* 1996; 223(2):268-273.
- [215] Tsujinaka T, Ebisui C, Fujita J et al.: Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. *Biochem Biophys Res Commun* 1995; 207(1):168-174.
- [216] Tsujinaka T, Ebisui C, Fujita J et al.: Autocatalytic inactivation of lysosomal cathepsins is associated with inhibition of protein breakdown by insulin-like growth factor-1 (IGF-1) in myotubes. *Biochem Biophys Res Commun* 1995; 208(1):353-359.
- [217] Turk B, Dolenc I, Turk V et al.: Kinetics of the pH-induced inactivation of human cathepsin L. *Biochemistry* 1993; 32(1):375-380.
- [218] Turman MA, Apple CA: Human proximal tubular epithelial cells express somatostatin: regulation by growth factors and cAMP. *Am J Physiol* 1998; 274(Pt 2):1095-1101.
- [219] Uchiyama Y, Watanabe M, Watanabe T et al.: Variations in immunocytochemical localization of cathepsin B and thyroxine in follicular cells of the rat thyroid gland and plasma TSH concentrations over 24 hours. *Cell Tissue Res* 1989; 256(2):355-360.
- [220] Uchiyama Y, Watanabe T, Watanabe M et al.: Immunocytochemical localization of cathepsins B, H, L, and T4 in follicular cells of rat thyroid gland. *J Histochem Cytochem* 1989; 37(5):691-696.

- [221] Ulbricht B, Hagmann W, Ebert W et al.: Differential secretion of cathepsins B and L from normal and tumor human lung cells stimulated by 12(S)-hydroxy-eicosatetraenoic acid. *Exp Cell Res* 1996; 226(2):255-263.
- [222] Ulbricht B, Spiess E, Schwartz-Albiez R et al.: Quantification of intracellular cathepsin activities in human lung tumor cell lines by flow cytometry. *Biol Chem Hoppe Seyler* 1995; 376(7):407-414.
- [223] Usuki K, Heldin NE, Miyazono K et al.: Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. *Proc Natl Acad Sci U S A* 1989; 86(19):7427-7431.
- [224] Van Keymeulen A, Dumont JE, Roger PP: TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells. *Biochem Biophys Res Commun* 2000; 279(1):202-207.
- [225] Van Keymeulen A, Roger PP, Dumont JE et al.: TSH and cAMP do not signal mitogenesis through Ras activation. *Biochem Biophys Res Commun* 2000; 273(1):154-158.
- [226] Van Zoelen EJ, Stortelers C, Lenferink AE et al.: The EGF domain: requirements for binding to receptors of the ErbB family. *Vitam Horm* 2000; 59:99-131.
- [227] Vasiljeva O, Papazoglou A, Kruger A et al.: Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. *Cancer Res* 2006; 66(10):5242-5250.
- [228] Veale D, Kerr N, Gibson GJ et al.: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. *Br J Cancer* 1993; 68(1):162-165.
- [229] Volkel H, Kurz U, Linder J et al.: Cathepsin L is an intracellular and extracellular protease in *Paramecium tetraurelia*. Purification, cloning, sequencing and specific inhibition by its expressed propeptide. *Eur J Biochem* 1996; 238(1):198-206.
- [230] Waguri S, Sato N, Watanabe T et al.: Cysteine proteinases in GH4C1 cells, a rat pituitary tumor cell line, are secreted by the constitutive and regulated secretory pathways. *Eur J Cell Biol* 1995; 67(4):308-318.
- [231] Weber E, Gunther D, Laube F et al.: Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth. *J Cancer Res Clin Oncol* 1994; 120(9):564-567.
- [232] Weinberg RA: *Wie Krebs entsteht. Spektrum der Wissenschaft*, Heidelberg, 1996.
- [233] Werle B, Ebert W, Klein W et al.: Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. *Biol Chem Hoppe Seyler* 1995; 376(3):157-164.
- [234] Werle B: *Cathepsin B aus Humanen Lungentumoren*. Med. Dissertation, Medizinische Fakultät, Ruprecht-Karls-Universität zu Heidelberg, 1997.
- [235] Werner SC, Ingbar SH, Braverman LE et al.: *Werner & Ingbar's the thyroid a fundamental and clinical text*. 8th ed ed. Lippincott Williams & Wilkins, Philadelphia, 2000.
- [236] Westermarck K: Epidermal Growth Factor Receptors and Receptor Localization in Thyroid Follicle Cells. In: Goretzki PE, Röher HD (Eds): *Frontiers of Hormone Research: Growth Regulation of Thyroid Gland and Thyroid Tumors*. Karger, Basel, 1989, pp. 28-34.
- [237] Williams D: Childhood Thyroid Cancer and Chernobyl. *Topical Endocrinology* 1996;(2):10-12.
- [238] Willstätter R, Bamann E: Über die Proteasen der Magenschleimhaut. Eine erste Abhandlung über die Enzyme der Leukozyten. *Hoppe-Seylers Z physiologische Chemie*, Berlin, 1929.
- [239] Wright WW, Zabudoff SD, Penttila TL et al.: Germ cell-Sertoli cell interactions: regulation by germ cells of the stage-specific expression of CP-2/cathepsin L mRNA by Sertoli cells. *Dev Genet* 1995; 16(2):104-113.
- [240] Yamaguchi N, Chung SM, Shiroeda O et al.: Characterization of a cathepsin L-like enzyme secreted from human pancreatic cancer cell line HPC-YP. *Cancer Res* 1990; 50(3):658-663.
- [241] Yamamoto H, Murawaki Y, Kawasaki H: Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver. *Res Commun Chem Pathol Pharmacol* 1992; 76(1):95-112.

- [242] Yan S, Sameni M, Sloane BF: Cathepsin B and human tumor progression. *Biol Chem* 1998; 379(2):113-123.
- [243] Yoshinari M, Taurog A: Lysosomal digestion of thyroglobulin: role of cathepsin D and thiol proteases. *Endocrinology* 1985; 117(4):1621-1631.